Impact of Type 2 Diabetes (T2D) Duration on Response to iGlarLixi vs. IGlar—A Subanalysis of LixiLan-L
Bibliographic record
Abstract
Shorter-acting GLP-1RA like lixisenatide have insulin-independent effects, which may benefit patients (pts) with longer T2D duration and more β-cell dysfunction. We assessed the effects of insulin glargine (iGlar) vs. fixed-ratio iGlar plus lixisenatide (iGlarLixi) by T2D duration in the LixiLan-L trial (N=736). HbA1c, weight, insulin dose change (BL-Wk 30) and hypoglycemia were analyzed in pts divided in quartiles by recorded baseline (BL) T2D duration (<7.3; 7.3-<10.7; 10.7-15.7; >15.7 years). Pts were also grouped by BL insulin dose (may relate inversely to β-cell function). BL HbA1c was higher in long-duration quartiles but similar with iGlarLixi vs. iGlar. iGlarLixi reduced HbA1c more vs. iGlar across duration quartiles (Figure). Difference was greater in pts in the longest duration quartile (LS mean difference [SE] -0.62 [0.13]; p<0.0001). In both treatment groups, pts in the shortest duration quartile had the greatest insulin dose change (BL-Wk 30). Difference in hypoglycemia (iGlarLixi vs. iGlar) was greatest in pts in the longest duration quartile (3.3 vs. 6.9 events/pt-yr; p<0.0001). In pts grouped by T2D duration and insulin dose, those with both long duration (>15.7 years) and high dose (>42 U) showed greatest difference in HbA1c lowering with iGlarLixi vs. iGlar. In LixiLan-L, iGlarLixi lowered HbA1c more vs. iGlar regardless of T2D duration, with greatest difference in those with longest duration. Disclosure L. Blonde: Other Relationship; Self; AstraZeneca. Speaker's Bureau; Self; AstraZeneca. Advisory Panel; Self; Intarcia Therapeutics, Inc.. Other Relationship; Self; Lexicon Pharmaceuticals, Inc.. Advisory Panel; Self; Janssen Pharmaceuticals, Inc.. Other Relationship; Self; Janssen Scientific Affairs, LLC.. Speaker's Bureau; Self; Janssen Pharmaceuticals, Inc.. Advisory Panel; Self; Merck & Co., Inc., Novo Nordisk Inc.. Speaker's Bureau; Self; Novo Nordisk Inc.. Other Relationship; Self; Novo Nordisk Inc., Sanofi. Advisory Panel; Self; Sanofi. Speaker's Bureau; Self; Sanofi US. L. Berard: Other Relationship; Self; Abbott, Becton, Dickinson and Company, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Sanofi, Montmed Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., LifeScan Canada. Consultant; Self; Ascensia Diabetes Care. Other Relationship; Self; Novo Nordisk Inc., Merck & Co., Inc. A. Saremi: Employee; Self; Sanofi US. Y. Huang: Consultant; Self; Sanofi. V. Aroda: Consultant; Self; Novo Nordisk Inc.. Research Support; Self; Novo Nordisk Inc., AstraZeneca, Calibra Medical, Eisai Inc., Sanofi. Consultant; Self; Sanofi. Research Support; Self; Theracos, Inc.. Employee; Spouse/Partner; Merck & Co., Inc.. Other Relationship; Self; American Diabetes Association. Consultant; Self; ADOCIA. D. Raccah: Advisory Panel; Self; Novo Nordisk Inc., Lilly, Sanofi, Merck & Co., Inc..
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.002 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.003 | 0.005 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".